Quitting Smoking Extends Life Even After a Stage 4 Cancer Diagnosis!
In this article
Quitting Smoking Extends Life Even After a Stage 4 Cancer Diagnosis!
A simple, often overlooked intervention may have an effect as powerful as surgery, radiotherapy, and systemic cancer treatments (chemotherapy, immunotherapy): quitting smoking.
Smoking remains responsible for approximately 30% of cancer deaths and 80% of lung cancer deaths . The harm persists not only before cancer develops but also after diagnosis . Quitting after a cancer diagnosis was already known to reduce symptom burden, improve treatment response, and lower second-cancer risk.
However, particularly in advanced-stage (Stage III–IV) patients , its effect on overall survival (OS) remained debated. Many clinicians placed cessation support second because they considered it “too late” at this stage.
A study published in October 2025 in JNCCNchanges that perspective: Tohmasi and colleagues' large 2025 cohort studyoffers strong evidence against this misconception. Based on real-world data, it showed that quitting smoking significantly extends survival not only in early-stage disease but even in advanced cancer patients .
These findings strongly reinforce that smoking cessation support should be the fourth pillar of oncology care alongside surgery, radiotherapy, and systemic treatment.
Study Details and Key Findings
Tohmasi and colleaguesconducted an observational cohort study from June to December 2018 at a major US cancer center (Alvin J. Siteman Cancer Center, Washington University), assessing 13,282 cancer patients . The aim was to examine how baseline smoking status and cessation within 6 months affected 2-year overall survival (OS) .
🔹 Smoking Status and Mortality Risk
Those smoking at baseline had a mortality risk, compared with never smokers, 35% higher (aHR: 1.35; 95% CI: 1.20–1.53).
For former smokers, the increase was %13 (aHR: 1.13; 95% CI: 1.03–1.25).
Two-year survival rates were:
- Never smokers: %81.4
- Former smokers: %79.4
- Current smokers: 76.4% (P<.001)
This difference was observed not only in tobacco-related cancers such as lung cancer, but across all cancer types and stages .
🔹 The Effect of Quitting After Cancer Diagnosis
Among patients smoking at baseline, only 22.1% of 1,725 patients (381 people) quit within 6 months. Yet this small group showed a dramatic difference:
- The mortality risk of those who continued smokingwas, compared with quitters, 97% higher (aHR: 1.97; 95% CI: 1.53–2.55).
- 2-year survival probability: Among quitters, %85.1, among continuing smokers, %74.7 (P<.001).
🔹 Effects in Advanced-Stage (III–IV) Cancer
The most striking finding was that even in advanced-stage (III–IV) patients, quitting significantly extended survival:
In advanced cancer patients, those continuing to smoke had a mortality risk 111% higher (aHR: 2.11; 95% CI: 1.60–2.79).
The surgical subgroup showed an even more striking difference: aHR: 4.408, meaning 4 times the mortality risk!
🏁 Conclusion and Clinical Implications: Oncology's Fourth Pillar
The message is clear: After a cancer diagnosis, quitting smokingdoes more than reduce symptoms; it substantially extends overall survival —even in advanced-stage (III–IV) patients.
What Should We Do Clinically?
- Regardless of stage, all patients who smoke should receive routine, structured cessation support .
- EHR-based approaches with low workload (e.g., care pathways combining advice + medication + behavioral support) should enter daily practice.
- Early follow-up (2–4 weeks) and repeated reminders should reinforce quit attempts; the first 6 months are a critical window .
- For surgical candidates, perioperative cessation support should become standard (in the surgical subgroup, aHR ≈ 4.4 reflected a substantial mortality difference).
What Do the Numbers Tell Us?
- Current smokers vs never smokers: mortality risk %35 higher (aHR: 1.35).
- Former smokers: risk %13 higher (aHR: 1.13).
- Those quitting within 6 months after diagnosis (%22.1): 2-year survival %85.1 (among continuing smokers, %74.7); continuing smokers had aHR: 1.97.
- Advanced-stage (III–IV) subgroup: mortality risk with continued smoking %111 higher (aHR: 2.11).
These data provide the rationale for placing cessation alongside surgery, radiotherapy, and chemotherapy/immunotherapy as a fourth pillar, based on evidence . For clinical teams, the most practical approach is to standardize automatic screening + immediate counseling + pharmacotherapytriggered in the same visit through EHR-supported workflows.
📚 References
- Tohmasi S, Baker TB, Heiden BT, et al. Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a NCI-Designated Cancer Center. J Natl Compr Canc Netw. 2025;23(10):e257059. DOI: 10.6004/jnccn.2025.7059
- National Cancer Institute. Treating Smoking in Cancer Patients: An Essential Component of Cancer Care. Monograph-23. Access: cancercontrol.cancer.gov
- Fiore MC, D’Angelo H, Baker T. Effective cessation treatment for patients with cancer who smoke — the fourth pillar of cancer care. JAMA Netw Open. 2019;2:e1912264.
🩺 For Whom, When, and Which Treatment?
Smoking cessation interventionsapply at every cancer stage, but should be tailored to clinical condition, treatment phase, and motivation.
| Patient Group | When to Intervene | Preferred Approach |
|---|---|---|
| Newly diagnosed (Stage I–II) | At diagnosis or before initial treatment planning | Motivational interviewing + Nicotine replacement + Behavioral support |
| Advanced stage (Stage III–IV) | At every treatment step (chemotherapy, immunotherapy, palliative care) | Low-dose varenicline or bupropion + close follow-up (2–4 weeks) |
| Surgical candidates | 4–6 weeks before surgery and the first 1 month afterward | Preoperative cessation support + NRT patches or varenicline |
| Recurrent or metastatic disease | Alongside symptom management, independently of treatment decisions | Low-dose pharmacotherapy + telephone/remote counseling |
💊 Medication Options
- Varenicline: Among the most effective agents. First 3 days: 0.5 mg/day, then 1 mg x2. 12 weeks; may extend to 24 weeks if needed.
- Bupropion SR: Start at 150 mg daily; from day 3, 150 mg x2. Its antidepressant effect makes it preferred when anxiety/depression coexists.
- Nicotine Replacement (NRT): Patch + gum/spray combinations work best. Particularly safe in surgical patients.
📅 Follow-Up and Monitoring
- The first 6 months are critical: Assess every 2–4 weeks.
- The first quit attempt fails in ≈ 60% —therefore, repeat attempts should be planned.
- Through EHR systems, automatic reminders (the ELEVATE model) improve cessation rates.
A Practical Guide: How to Say It to Patients
The right words can be as effective as treatment during smoking cessation. Here are brief, reassuring phrases that help when speaking with cancer patients 👇
- “To improve your treatment's effect, quitting smoking is as important as the chemotherapy you receive.”
- “It is never too late to quit. Studies show longer survival even in advanced-stage patients.”
- “Quitting strengthens not just your lungs but your body's response to treatment.”
- “You do not have to do this alone. With medication and counseling, we can work toward success together.”
- “Quitting also plays a major role in reducing symptoms such as fatigue, shortness of breath, and appetite loss.”
A brief reminder: Quitting happens through a process rather than all at once. Success at the first attempt is uncommon, but every attempt matters. The key for the clinical team: “a brief but consistent reminder at every visit”.
This keeps motivation alive and makes cessation a healing-focused behavior rather than a punitive one.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.